Crinetics Pharmaceuticals Earnings Preview
Portfolio Pulse from Benzinga Insights
Crinetics Pharmaceuticals (NASDAQ:CRNX) is scheduled to release its quarterly earnings report on February 28, 2024, with an estimated EPS of $-0.86. Analysts and investors will be looking for the company to beat this estimate and provide positive guidance for the next quarter. Historical data shows that the company's stock price reacts to both earnings performance and guidance. Last quarter, CRNX missed its EPS estimate by $0.10, resulting in a 3.62% drop in its share price. Over the last year, CRNX shares have increased by 100.99%, trading at $38.67 as of February 26.
February 27, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Crinetics Pharmaceuticals is expected to report an EPS of $-0.86 for the upcoming quarter. Historical performance shows sensitivity in stock price to earnings outcomes and guidance.
Given the historical sensitivity of CRNX's stock price to earnings performance and guidance, the upcoming earnings report could have a neutral to positive impact depending on whether they meet or exceed the EPS estimate and provide positive future guidance. The stock has shown significant growth over the past year, indicating investor confidence which could mitigate negative reactions to a potential earnings miss.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100